We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App

Genetic Analysis System Will Use Nanoscale Whole Genome Imaging Technology

By Biotechdaily staff writers
Posted on 13 Nov 2007
Print article
Nanoscale whole genome imaging and analytic platforms are being developed for applications in clinical genetics, cancer diagnostics, and other biomedical applications. Nanosystems technology provides fast, comprehensive, and low-cost analysis of genomic, epigenomic, and proteomic information with sensitivity at the single cell/single molecule level.

Agilent Technologies Inc. (Santa Clara, CA, USA) and BioNanomatrix Inc. (Philadelphia, PA, USA) have entered into a collaboration to develop a genetic analysis system. BioNanomatrix is developing technology that enables nanoscale single molecule identification and analysis of the entire genome, delivering single-molecule sensitivity in a highly parallel format. Agilent will provide the measurement instrumentation platform for the system.

BioNanomatrix's analytic platform has the potential to provide rapid, comprehensive, and cost-effective ultra-high resolution analyses of DNA. The two companies intend to collaborate closely in the development of an integrated system and applications.

"BioNanomatrix's unique nanoscale whole genome imaging and analysis technology, with sensitivity at the level of the single molecule, has the potential to enable a number of important new applications for life-sciences research and clinical medicine,” said Nick Roelofs, vice president and general manager of the life-sciences solutions unit at Agilent.

Dr. Michael Boyce-Jacino, CEO of BioNanomatrix said, "We now have a partner with strong life sciences expertise and capabilities committed to working with us to develop key life- sciences applications, such as assays for genotoxicity and cytogenetics, as well as potentially DNA sequencing.”

Related Links:
Gold Supplier
Fluorimetric Immunoassay Analyzer
Confiscope F20
Atomic Fluorescence Spectrometer
Integrated Urinalysis Chemistry Analyzer
Microplate Reader

Print article
IIR Middle East


Molecular Diagnostics

view channel

Point-of-Care Lateral Flow Test Detects Bladder Cancer Using Urine Sample within Minutes

A breakthrough diagnostics platform uses a multiplexed lateral flow assay that detects 10 bladder cancer biomarkers from a urine sample in either laboratory or point-of-care settings. SCIENION (Berlin,... Read more


view channel
Image: Bone marrow aspirate from a patient with Acute Myeloid Leukemia: Blasts are the predominant population and have a high nuclear to cytoplasmic ratio and generally lack granules. (Photo courtesy of Professor Peter G. Maslak, MD)

Cord Blood and Matched Related Donor Transplantation Compared in Acute Myeloid Leukemia

The prognosis of primary refractory and relapsed acute myeloid leukemia is poor, with a five-year overall survival of less than 10%. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only... Read more


view channel

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.